Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment Bumbea H; Vladareanu AM; Voican I; Cisleanu D; Barsan L; Onisai MJ Med Life 2010[Apr]; 3 (2): 162-6Chronic Myeloid Leukemia is the first malignant disorder with a specific genetic abnormality in the background. Known as a disease with an inexorable progression to acute leukemia for many years, its natural history has been dramatically improved by the use of tyrosine kinase inhibitors (TKI). They represent the first molecular targeted therapy addressed to a neoplastic disorder. From these new classes of drugs, Imatinib was the first drug ever used, and it remains the standard therapy for patients in chronic phase with CML, having a global survival of 86%, for 7 years. The 2nd generation of TKI (Dasatinib, Nilotinib) is indicated for the patients who are refractory or intolerant to Imatinib. The other TKI have good promises to be efficient on the mutations of BCR-ABL transcript, especially to non-responsive T315I mutation.|Benzamides[MESH]|Dasatinib[MESH]|Drug Resistance, Neoplasm[MESH]|Genes, abl[MESH]|Humans[MESH]|Imatinib Mesylate[MESH]|Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy/genetics[MESH]|Piperazines/administration & dosage/adverse effects/therapeutic use[MESH]|Protein Kinase Inhibitors/administration & dosage/adverse effects/*therapeutic use[MESH]|Protein-Tyrosine Kinases/*antagonists & inhibitors[MESH]|Pyrimidines/administration & dosage/adverse effects/therapeutic use[MESH]|Thiazoles/therapeutic use[MESH] |